Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.

Also called NCT01880216

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 312 participants (enrolled count) (from the registry)
Sponsor
Berlin-Chemie AG Menarini Group (from the registry)
Registry
  • NCT NCT01880216
Other papers using this trial's data
  • Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial Clinical drug investigation, 2018-02 DOI, PubMed 29214507

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Georgia, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01880216. Randomized; single masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Intervention (Drug)
Bemiparin sodium
Intervention (Drug)
Enoxaparin sodium
Lead sponsor
Berlin-Chemie AG Menarini Group (class: industry)

Record details

Record id
cardio:ct-nct01880216
Content hash
1ac5223620f11cef62028d9b1631ae93de3df7146fb703bbbb873a4129dc2f66